187 related articles for article (PubMed ID: 22454481)
1. Poly(ADP-ribose) polymerase 1 inhibition improves coronary arteriole function in type 2 diabetes mellitus.
Choi SK; Galán M; Kassan M; Partyka M; Trebak M; Matrougui K
Hypertension; 2012 May; 59(5):1060-8. PubMed ID: 22454481
[TBL] [Abstract][Full Text] [Related]
2. Enhanced NF-κB activity impairs vascular function through PARP-1-, SP-1-, and COX-2-dependent mechanisms in type 2 diabetes.
Kassan M; Choi SK; Galán M; Bishop A; Umezawa K; Trebak M; Belmadani S; Matrougui K
Diabetes; 2013 Jun; 62(6):2078-87. PubMed ID: 23349490
[TBL] [Abstract][Full Text] [Related]
3. Elevated epidermal growth factor receptor phosphorylation induces resistance artery dysfunction in diabetic db/db mice.
Belmadani S; Palen DI; Gonzalez-Villalobos RA; Boulares HA; Matrougui K
Diabetes; 2008 Jun; 57(6):1629-37. PubMed ID: 18319304
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice.
Szabó C; Biser A; Benko R; Böttinger E; Suszták K
Diabetes; 2006 Nov; 55(11):3004-12. PubMed ID: 17065336
[TBL] [Abstract][Full Text] [Related]
5. Enhanced p22phox expression impairs vascular function through p38 and ERK1/2 MAP kinase-dependent mechanisms in type 2 diabetic mice.
Kassan M; Choi SK; Galán M; Lee YH; Trebak M; Matrougui K
Am J Physiol Heart Circ Physiol; 2014 Apr; 306(7):H972-80. PubMed ID: 24486509
[TBL] [Abstract][Full Text] [Related]
6. Poly-ADP-ribose polymerase inhibition enhances ischemic and diabetic wound healing by promoting angiogenesis.
Zhou X; Patel D; Sen S; Shanmugam V; Sidawy A; Mishra L; Nguyen BN
J Vasc Surg; 2017 Apr; 65(4):1161-1169. PubMed ID: 27288104
[TBL] [Abstract][Full Text] [Related]
7. Rapid reversal of the diabetic endothelial dysfunction by pharmacological inhibition of poly(ADP-ribose) polymerase.
Soriano FG; Pacher P; Mabley J; Liaudet L; Szabó C
Circ Res; 2001 Oct; 89(8):684-91. PubMed ID: 11597991
[TBL] [Abstract][Full Text] [Related]
8. Poly(ADP-ribose) polymerase 1 inhibition protects cardiomyocytes from inflammation and apoptosis in diabetic cardiomyopathy.
Qin WD; Liu GL; Wang J; Wang H; Zhang JN; Zhang F; Ma Y; Ji XY; Li C; Zhang MX
Oncotarget; 2016 Jun; 7(24):35618-35631. PubMed ID: 27027354
[TBL] [Abstract][Full Text] [Related]
9. PARP-1 inhibition alleviates diabetic cardiac complications in experimental animals.
Zakaria EM; El-Bassossy HM; El-Maraghy NN; Ahmed AF; Ali AA
Eur J Pharmacol; 2016 Nov; 791():444-454. PubMed ID: 27612628
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.
Pacher P; Liaudet L; Mabley JG; Cziráki A; Haskó G; Szabó C
Int J Mol Med; 2006 Feb; 17(2):369-75. PubMed ID: 16391839
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors Reduce Reactive Gliosis and Improve Angiostatin Levels in Retina of Diabetic Rats.
Guzyk MM; Tykhomyrov AA; Nedzvetsky VS; Prischepa IV; Grinenko TV; Yanitska LV; Kuchmerovska TM
Neurochem Res; 2016 Oct; 41(10):2526-2537. PubMed ID: 27255598
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
13. A nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist reverses endothelial dysfunction in diabetic (db/db-/-) mice.
Howarth AG; Wiehler WB; Pannirselvam M; Jiang Y; Berger JP; Severson D; Anderson TJ; Triggle CR
J Pharmacol Exp Ther; 2006 Jan; 316(1):364-70. PubMed ID: 16249369
[TBL] [Abstract][Full Text] [Related]
14. Poly(Adenosine 5'-diphosphate-ribose) polymerase inhibition counteracts multiple manifestations of experimental type 1 diabetic nephropathy.
Drel VR; Xu W; Zhang J; Pavlov IA; Shevalye H; Slusher B; Obrosova IG
Endocrinology; 2009 Dec; 150(12):5273-83. PubMed ID: 19854869
[TBL] [Abstract][Full Text] [Related]
15. AdipoRon, adiponectin receptor agonist, improves vascular function in the mesenteric arteries of type 2 diabetic mice.
Choi SK; Kwon Y; Byeon S; Haam CE; Lee YH
PLoS One; 2020; 15(3):e0230227. PubMed ID: 32182257
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) polymerase inhibition reverses nitrergic neurovascular dysfunctions in penile erectile tissue from streptozotocin-diabetic mice.
Nangle MR; Cotter MA; Cameron NE
J Sex Med; 2010 Oct; 7(10):3396-403. PubMed ID: 20456626
[TBL] [Abstract][Full Text] [Related]
17. O-GlcNAcase overexpression reverses coronary endothelial cell dysfunction in type 1 diabetic mice.
Makino A; Dai A; Han Y; Youssef KD; Wang W; Donthamsetty R; Scott BT; Wang H; Dillmann WH
Am J Physiol Cell Physiol; 2015 Nov; 309(9):C593-9. PubMed ID: 26269457
[TBL] [Abstract][Full Text] [Related]
18. Nuclear factor kappa B inhibition improves conductance artery function in type 2 diabetic mice.
Kassan M; Choi SK; Galán M; Trebak M; Belmadani S; Matrougui K
Diabetes Metab Res Rev; 2015 Jan; 31(1):39-49. PubMed ID: 24652705
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) polymerase inhibition improves erectile function by activation of nitric oxide/cyclic guanosine monophosphate pathway in diabetic rats.
Li WJ; Peng Y; Zhou J; Li B; Wang H; Zhang J; Wang Z
J Sex Med; 2012 May; 9(5):1319-27. PubMed ID: 22429732
[TBL] [Abstract][Full Text] [Related]
20. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
